Product Information
REXULTI 4 MG TABLET is a brand product labeled by Otsuka America Pharmaceutical Inc., priced at $49.4674 per EA under NDC 59148004013. Its NADAC has been published 546 times since Apr 20, 2016.
FDA first approved this application on Jul 10, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
4 mg/1
Manufacturer
Otsuka America Pharmaceutical Inc.NDC
59148004013
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BREXPIPRAZOLEApproval Type
New Drug (NDA)
FDA Application
NDA205422FDA Approved
7/10/2015
TE Code
AB
On Market Since
7/10/2015
Pharmacological Classes
Price Statistics
The NADAC for REXULTI 4 MG TABLET has been published 546 times since Apr 20, 2016, and over the history we have for it it has risen 74.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $49.4674 per EA |
|---|---|
| All-time high | $49.6310 (May 13, 2026) |
| All-time low | $28.3809 (Apr 20, 2016) |
| 52-week high | $49.6310 |
| 52-week low | $48.2848 |
| Median price | $39.7070 |
| Average price | $40.2403 |
| Largest weekly change | +9.9% (Apr 11, 2018) |
| Weeks tracked | 546 |
| Tracking since | Apr 20, 2016 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the brexpiprazole market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Otsuka America Pharmaceutical Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
brexpiprazole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of REXULTI 4 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for REXULTI 4 MG TABLET, manufactured by Otsuka America Pharmaceutical Inc., is $49.4674 per EA (NDC 59148004013), effective Sep 30, 2026.
How has the price of REXULTI 4 MG TABLET changed over time?
Over the history we have for it, the NADAC for REXULTI 4 MG TABLET has risen 74.3%. It has been tracked across 546 weekly CMS publications since Apr 20, 2016.
What are the highest and lowest recorded NADAC prices for REXULTI 4 MG TABLET?
Since Apr 20, 2016, the NADAC for REXULTI 4 MG TABLET has ranged from a low of $28.3809 (Apr 20, 2016) to a high of $49.6310 (May 13, 2026), with a median of $39.7070 per EA.
Are there cheaper alternatives to REXULTI 4 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of REXULTI 4 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures REXULTI 4 MG TABLET?
REXULTI 4 MG TABLET (NDC 59148004013) is labeled by Otsuka America Pharmaceutical Inc., and CMS classifies it as a brand product.